Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myelomaMichèle Cavo, Antonio Palumbo, Lucia Pantani et al.|Blood|2012Cited by 310
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)Domenico Russo, Anna Paola Iori, Francesco Zallio et al.|Bone Marrow Transplantation|2021Cited by 20
A PHASE III STUDY OF ENOXAPARIN VS ASPIRIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED OF MULTIPLE MYELOMA TREATED WITH LENALIDOMIDE-BASED REGIMENS.Federica Cavallo, Antonio Palumbo, Tommaso Caravita et al.|Unknown|2011Cited by 3
Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)Paola Tacchetti, Michèle Cavo, Carolina Terragna et al.|Blood|2011Cited by 1
Thromboprophylaxis for Newly Diagnosed Multiplemyeloma Patients Treated With Lenalidomide-Basedregimens: A Randomized Phase Iii Study of Aspirinvs EnoxaparinAlessandra Larocca, Antonio Palumbo, Adriane Feijó Evangelista et al.|Unknown|2011Cited by 0